查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1573230

化疗引起的周边神经病变治疗市场：依治疗类型、治疗阶段、患者特征、治疗环境、治疗持续时间、药物作用机制 - 2025-2030 年全球预测

Chemotherapy Induced Peripheral Neuropathy Treatment Market by Treatment Types, Stages Of Treatment, Patient Demographics, Treatment Settings, Duration Of Treatment, Drug Mechanism Of Action - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

化疗引起的周边神经神经病变治疗市场2023年估值为9.0535亿美元，预计2024年将达到9.7424亿美元，复合年增长率为7.91%，到2030年将达15%，预计将达到4328万亿美元。

化疗引起的周边神经病变（CIPN）是癌症治疗的常见副作用，其特征是化疗药物引起週边神经损伤。对有效 CIPN 治疗的需求源于改善患者生活品质和提高正在进行的癌症治疗的耐受性的需要。应用范围包括神经保护剂和镇痛药等药物干预、物理治疗等非药物治疗以及基因治疗和医疗设备等实验方法。最终用户主要是医院、肿瘤中心和研究机构。

主要市场统计
基准年[2023] 90535万美元
预测年份 [2024] 97424万美元
预测年份 [2030] 15.4328亿美元
复合年增长率（%） 7.91%

市场成长要素包括癌症发生率上升、全球化疗使用增加以及患者对治疗副作用的认识不断提高，这些都推动了 CIPN 治疗的需求。技术的进步和正在进行的研究正在创造利润丰厚的机会，提供开发新药和针对基因谱量身定制的个人化医疗等可能性。为了利用这些优势，相关人员应该投资于研发，促进生技公司之间的合作，并加强对 CIPN 治疗的市场宣导活动。

CIPN 病理学的复杂性使得开拓治疗方法变得困难，而高昂的研发成本和监管障碍又减缓了产品的推出。此外，患者对治疗反应的可变性使有效治疗方法的标准化变得复杂。应对这些挑战需要增加基础研究资金、简化监管途径并增加国际临床试验以统一护理标准。

创新领域在于开发副作用最小的标靶治疗、利用即时资料分析进行病患监测以及探索具有治疗潜力的天然化合物。未满足需求的规模凸显了市场竞争，正在促使大型製药公司和学术机构之间进行合作，以加速治疗进展。专注于以患者为中心的方法，将人工智慧融入临床研究以进行预测分析，以及开拓的多功能治疗平台将显着推动市场成长，并确保 CIPN 治疗领域的业务持续扩张。

市场动态：快速发展的化疗引起的周边神经病变治疗市场的关键市场洞察

化疗引起的周边神经神经病变治疗市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 扩大发展中地区的医疗基础设施和服务范围
    • 製药公司与研究机构之间的新疗法合作
    • 支持癌症治疗和神经病变管理的政府措施和资金
    • 将远端医疗和数位健康解决方案整合到神经病变治疗通讯协定中
  • 市场限制因素
    • 化疗週边神经病变的临床试验设计所面临的挑战
    • 化疗引起的周边神经病变新治疗方法获得核准的监管障碍
  • 市场机会
    • 与製药公司合作开发针对化疗引起的周边神经病变的创新药物配方
    • 利用人工智慧和机器学习为化疗引起的周边神经神经病变制定个人化治疗计划
    • 探索饮食和生活方式干预措施以补充传统化疗引起的周边神经病变治疗
  • 市场挑战
    • 解决化疗引起的周边神经病变合併治疗的复杂性
    • 神经病变治疗市场的临床试验设计与病患招募挑战

波特的五力：导航化疗引起的周边神经病变治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解化疗引起的周边神经病变治疗市场的外部影响

外部宏观环境因素在塑造化疗引起的周边神经神经病变治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解化疗引起的周边神经病变治疗市场的竞争格局

对化疗引起的周边神经神经病变治疗市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位基质化疗诱发週边神经神经病变治疗市场供应商的表现评估

FPNV 定位矩阵是评估化疗引起的周边神经病变治疗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了化疗引起的周边神经病变治疗市场的成功之路

对化疗引起的周边神经神经病变治疗市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 扩大发展中地区的医疗基础设施和服务范围
      • 製药公司与研究机构联合研究新治疗方法
      • 支持癌症治疗和神经病变管理的政府措施和资金
      • 将远端医疗和数位健康解决方案整合到神经病变治疗通讯协定中
    • 抑制因素
      • 治疗化疗引起的周边神经病变的临床试验设计面临的挑战
      • 核准化疗引起的周边神经病变新治疗方法的监管障碍
    • 机会
      • 与製药公司合作开发针对化疗引起的周边神经病变的创新药物配方
      • 利用人工智慧和机器学习为化疗引起的周边神经神经病变制定个人化治疗计划
      • 检查饮食和生活方式干预措施以补充传统化疗引起的周边神经病变治疗
    • 任务
      • 化疗引起的周边神经病变合併治疗的复杂性
      • 神经病变治疗市场中临床试验设计与病患招募的挑战
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章化疗引起的周边神经病变治疗市场（依治疗类型）

  • 非药物治疗
    • 针刺
    • 认知行为疗法
    • 职能治疗
    • 物理治疗
    • 经皮神经电刺激 (TENS)
  • 药物治疗
    • 抗惊厥药
    • 抗忧郁症
    • 食品补充品
    • 阿片类止痛药
    • 外用製剂

第七章化疗引起的周边神经病变治疗市场（依治疗阶段）

  • 高级阶段
  • 最初的
  • 中场

第八章化疗引起的周边神经神经病变治疗市场病人细分

  • 年龄组
    • 成人用
    • 老年病
    • 小儿科
  • 性别
    • 女士
    • 男人
  • 患者病历
    • 遗传因素
    • 既往病史
    • 既往化疗

第九章化疗引起的周边神经病变治疗市场（依治疗环境）

  • 居家护理
  • 医院
  • 专科诊所

第10章化疗引起的周边神经神经病变治疗市场（依治疗持续时间划分）

  • 长期
  • 短期

第十一章化疗引起的周边神经神经病变治疗市场药物按作用机制

  • 钙离子通道调节剂
  • γ-胺基丁酸 (GABA) 类似物
  • 阿片类药物
  • 正肾上腺素再回收抑制剂(SNRI)

第十二章美洲化疗引起的周边神经神经病变治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十三章亚太地区化疗引起的周边神经神经病变治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第14章欧洲、中东和非洲化疗引起的周边神经神经病变治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C04DA

The Chemotherapy Induced Peripheral Neuropathy Treatment Market was valued at USD 905.35 million in 2023, expected to reach USD 974.24 million in 2024, and is projected to grow at a CAGR of 7.91%, to USD 1,543.28 million by 2030.

Chemotherapy Induced Peripheral Neuropathy (CIPN) is a prevalent adverse effect of cancer treatment, characterized by damage to the peripheral nerves due to chemotherapy drugs. The necessity for effective CIPN treatment stems from the need to improve patients' quality of life and enhance the tolerability of ongoing cancer therapies. The application scope encompasses pharmaceutical interventions like neuroprotective agents and analgesics, non-pharmacological therapies such as physical therapy, and experimental approaches including gene therapy and medical devices. End-users primarily include hospitals, oncology centers, and research institutions.

KEY MARKET STATISTICS
Base Year [2023] USD 905.35 million
Estimated Year [2024] USD 974.24 million
Forecast Year [2030] USD 1,543.28 million
CAGR (%) 7.91%

Market growth factors include the rising incidence of cancer, increasing chemotherapy usage globally, and growing patient awareness about treatment side effects, driving demand for CIPN therapies. Technological advancements and ongoing research offer potentials like novel drug development and personalized medicine tailored to genetic profiles, presenting lucrative opportunities. To capitalize on these, stakeholders should invest in R&D, foster collaborations among biotech firms, and enhance market education initiatives about CIPN treatments.

However, several limitations challenge market expansion: the complexity of CIPN pathology makes treatment development difficult, alongside high R&D costs and regulatory hurdles delaying product launches. Additionally, variability in patient responses to treatments complicates the standardization of effective therapies. Addressing these challenges requires increased funding for basic research, streamlined regulatory pathways, and more international clinical trials to unify treatment standards.

Innovation areas lie in developing targeted therapies with minimal side effects, employing real-time data analytics for patient monitoring, and exploring natural compounds with therapeutic potential. The market's competitive nature is underscored by substantial unmet needs, prompting alliances among pharmaceutical giants and academic institutions to expedite therapy advancements. Emphasizing patient-centric approaches, integrating AI in clinical studies for predictive analyses, and developing multifunctional treatment platforms could significantly propel market growth, ensuring sustainable business expansion in the CIPN treatment landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Chemotherapy Induced Peripheral Neuropathy Treatment Market

The Chemotherapy Induced Peripheral Neuropathy Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Expansion of healthcare infrastructure and access in developing regions
    • Collaborations between pharmaceutical companies and research institutions for novel therapies
    • Government initiatives and funding to support cancer treatment and neuropathy management
    • Integration of telemedicine and digital health solutions in neuropathy treatment protocols
  • Market Restraints
    • Challenges in clinical trial design for chemotherapy induced peripheral neuropathy treatments
    • Regulatory hurdles in gaining approval for new chemotherapy induced peripheral neuropathy therapies
  • Market Opportunities
    • Collaborating with pharmaceutical companies for breakthrough drug formulations targeting chemotherapy induced peripheral neuropathy
    • Utilizing artificial intelligence and machine learning for personalized treatment plans in chemotherapy induced peripheral neuropathy
    • Exploring dietary and lifestyle interventions to complement traditional chemotherapy induced peripheral neuropathy treatments
  • Market Challenges
    • Navigating the complexities of combination treatments for chemotherapy-induced peripheral neuropathy
    • Challenges in clinical trial design and patient recruitment in neuropathy treatment market

Porter's Five Forces: A Strategic Tool for Navigating the Chemotherapy Induced Peripheral Neuropathy Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Chemotherapy Induced Peripheral Neuropathy Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Chemotherapy Induced Peripheral Neuropathy Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Chemotherapy Induced Peripheral Neuropathy Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Chemotherapy Induced Peripheral Neuropathy Treatment Market

A detailed market share analysis in the Chemotherapy Induced Peripheral Neuropathy Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Chemotherapy Induced Peripheral Neuropathy Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Chemotherapy Induced Peripheral Neuropathy Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Chemotherapy Induced Peripheral Neuropathy Treatment Market

A strategic analysis of the Chemotherapy Induced Peripheral Neuropathy Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chemotherapy Induced Peripheral Neuropathy Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Asahi Kasei Corporation, Astellas Pharma Inc., AstraZeneca PLC, Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Glenmark Pharmaceuticals Ltd., Ipsen Pharma, Johnson & Johnson, Kyowa Kirin Co., Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Purdue Pharma L.P., Regenacy Pharmaceuticals LLC, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Chemotherapy Induced Peripheral Neuropathy Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Types, market is studied across Non-Pharmacological Treatments and Pharmacological Treatments. The Non-Pharmacological Treatments is further studied across Acupuncture, Cognitive Behavioral Therapy, Occupational Therapy, Physical Therapy, and Transcutaneous Electrical Nerve Stimulation (TENS). The Pharmacological Treatments is further studied across Anticonvulsants, Antidepressants, Nutritional Supplements, Opioid Analgesics, and Topical Agents.
  • Based on Stages Of Treatment, market is studied across Advanced Stage, Initial Stage, and Mid Stage.
  • Based on Patient Demographics, market is studied across Age Group, Gender, and Patient History. The Age Group is further studied across Adult, Geriatric, and Pediatric. The Gender is further studied across Female and Male. The Patient History is further studied across Genetic Factors, Pre-existing Conditions, and Previous Chemotherapy Treatments.
  • Based on Treatment Settings, market is studied across Homecare, Hospitals, and Specialty Clinics.
  • Based on Duration Of Treatment, market is studied across Long Term and Short Term.
  • Based on Drug Mechanism Of Action, market is studied across Calcium Channel Modulators, Gamma-Aminobutyric Acid (GABA) Analogues, Opioids, and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs).
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Expansion of healthcare infrastructure and access in developing regions
      • 5.1.1.2. Collaborations between pharmaceutical companies and research institutions for novel therapies
      • 5.1.1.3. Government initiatives and funding to support cancer treatment and neuropathy management
      • 5.1.1.4. Integration of telemedicine and digital health solutions in neuropathy treatment protocols
    • 5.1.2. Restraints
      • 5.1.2.1. Challenges in clinical trial design for chemotherapy induced peripheral neuropathy treatments
      • 5.1.2.2. Regulatory hurdles in gaining approval for new chemotherapy induced peripheral neuropathy therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaborating with pharmaceutical companies for breakthrough drug formulations targeting chemotherapy induced peripheral neuropathy
      • 5.1.3.2. Utilizing artificial intelligence and machine learning for personalized treatment plans in chemotherapy induced peripheral neuropathy
      • 5.1.3.3. Exploring dietary and lifestyle interventions to complement traditional chemotherapy induced peripheral neuropathy treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Navigating the complexities of combination treatments for chemotherapy-induced peripheral neuropathy
      • 5.1.4.2. Challenges in clinical trial design and patient recruitment in neuropathy treatment market
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Treatment Types

  • 6.1. Introduction
  • 6.2. Non-Pharmacological Treatments
    • 6.2.1. Acupuncture
    • 6.2.2. Cognitive Behavioral Therapy
    • 6.2.3. Occupational Therapy
    • 6.2.4. Physical Therapy
    • 6.2.5. Transcutaneous Electrical Nerve Stimulation (TENS)
  • 6.3. Pharmacological Treatments
    • 6.3.1. Anticonvulsants
    • 6.3.2. Antidepressants
    • 6.3.3. Nutritional Supplements
    • 6.3.4. Opioid Analgesics
    • 6.3.5. Topical Agents

7. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Stages Of Treatment

  • 7.1. Introduction
  • 7.2. Advanced Stage
  • 7.3. Initial Stage
  • 7.4. Mid Stage

8. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Patient Demographics

  • 8.1. Introduction
  • 8.2. Age Group
    • 8.2.1. Adult
    • 8.2.2. Geriatric
    • 8.2.3. Pediatric
  • 8.3. Gender
    • 8.3.1. Female
    • 8.3.2. Male
  • 8.4. Patient History
    • 8.4.1. Genetic Factors
    • 8.4.2. Pre-existing Conditions
    • 8.4.3. Previous Chemotherapy Treatments

9. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Treatment Settings

  • 9.1. Introduction
  • 9.2. Homecare
  • 9.3. Hospitals
  • 9.4. Specialty Clinics

10. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Duration Of Treatment

  • 10.1. Introduction
  • 10.2. Long Term
  • 10.3. Short Term

11. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Drug Mechanism Of Action

  • 11.1. Introduction
  • 11.2. Calcium Channel Modulators
  • 11.3. Gamma-Aminobutyric Acid (GABA) Analogues
  • 11.4. Opioids
  • 11.5. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

12. Americas Chemotherapy Induced Peripheral Neuropathy Treatment Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Asahi Kasei Corporation
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca PLC
  • 5. Biogen Inc.
  • 6. Bristol-Myers Squibb Company
  • 7. Eli Lilly and Company
  • 8. Glenmark Pharmaceuticals Ltd.
  • 9. Ipsen Pharma
  • 10. Johnson & Johnson
  • 11. Kyowa Kirin Co., Ltd.
  • 12. Merck & Co., Inc.
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Purdue Pharma L.P.
  • 16. Regenacy Pharmaceuticals LLC
  • 17. Sanofi S.A.
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OPIOID ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TOPICAL AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INITIAL STAGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY MID STAGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENETIC FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PRE-EXISTING CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PREVIOUS CHEMOTHERAPY TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY LONG TERM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SHORT TERM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY CALCIUM CHANNEL MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GAMMA-AMINOBUTYRIC ACID (GABA) ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 134. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 136. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 138. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 140. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 145. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 146. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 147. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 148. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 149. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 150. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 151. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 152. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 153. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 155. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 156. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 157. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 158. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 160. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 161. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 162. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 163. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 164. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 165. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 166. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 167. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 168. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 169. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 170. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 171. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 172. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 173. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 174. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 175. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 176. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 177. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 178. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 179. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 180. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 182. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 183. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 184. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 185. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 186. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 187. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 188. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 189. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 190. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 191. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 192. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 193. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 194. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 195. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 196. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 197. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 198. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 200. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 202. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 204. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 205. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 206. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 207. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 208. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 209. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 210. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 211. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 212. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 213. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 214. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 215. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 216. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 217. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 218. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 219. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 220. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 222. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 223. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 224. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 225. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 226. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 227. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 228. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 229. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 230. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 232. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 233. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 234. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 235. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 236. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 237. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 238. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 239. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT HISTORY, 2018-2030 (USD MILLION)
  • TABLE 240. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 241. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DURATION OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 242. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY DRUG MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 243. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPES, 2018-2030 (USD MILLION)
  • TABLE 244. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 245. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 246. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STAGES OF TREATMENT, 2018-2030 (USD MILL